Inhibitor Therapeutics, Inc. (INTI)
USD 0.06
(20.0%)
USD 0.06
(20.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -8.83 Million USD | 23.4% |
| 2022 | -11.54 Million USD | -5859.34% |
| 2021 | 200.37 Thousand USD | 830.2% |
| 2020 | 21.54 Thousand USD | 102.68% |
| 2019 | -803.81 Thousand USD | 27.5% |
| 2018 | -1.1 Million USD | -222.19% |
| 2017 | -344.11 Thousand USD | 95.0% |
| 2016 | -6.88 Million USD | -1044.81% |
| 2015 | -601.44 Thousand USD | -64.71% |
| 2014 | -365.16 Thousand USD | -635.34% |
| 2013 | 68.21 Thousand USD | 107.95% |
| 2012 | -857.7 Thousand USD | -30.89% |
| 2011 | -655.3 Thousand USD | -119.33% |
| 2010 | 3.38 Million USD | -9.51% |
| 2009 | 3.74 Million USD | -24.67% |
| 2008 | 4.97 Million USD | 47.72% |
| 2007 | 3.36 Million USD | 59.52% |
| 2006 | 2.11 Million USD | 23.54% |
| 2005 | 1.7 Million USD | -2.34% |
| 2004 | 1.74 Million USD | -49.09% |
| 2003 | 3.43 Million USD | -5.5% |
| 2002 | 3.63 Million USD | -10.05% |
| 2001 | 4.04 Million USD | 5.44% |
| 2000 | 3.83 Million USD | -13.88% |
| 1999 | 4.45 Million USD | 111.91% |
| 1998 | 2.1 Million USD | 135.0% |
| 1997 | -6 Million USD | -5900.0% |
| 1996 | -100 Thousand USD | -211.11% |
| 1995 | 90 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -7.09 Million USD | 7.59% |
| 2024 Q1 | -7.68 Million USD | 13.1% |
| 2023 Q2 | -10.1 Million USD | 6.33% |
| 2023 Q3 | -9.53 Million USD | 5.57% |
| 2023 Q4 | -8.83 Million USD | 7.32% |
| 2023 FY | -8.83 Million USD | 23.4% |
| 2023 Q1 | -10.78 Million USD | 6.56% |
| 2022 Q4 | -11.54 Million USD | -3324.05% |
| 2022 Q3 | 357.94 Thousand USD | 16.95% |
| 2022 Q2 | 306.05 Thousand USD | 25.14% |
| 2022 FY | -11.54 Million USD | -5859.34% |
| 2022 Q1 | 244.56 Thousand USD | 22.05% |
| 2021 FY | 200.37 Thousand USD | 830.2% |
| 2021 Q3 | 177.71 Thousand USD | 29.45% |
| 2021 Q4 | 200.37 Thousand USD | 12.75% |
| 2021 Q1 | 71.81 Thousand USD | 233.37% |
| 2021 Q2 | 137.28 Thousand USD | 91.17% |
| 2020 Q4 | 21.54 Thousand USD | 340.24% |
| 2020 Q3 | 4893.00 USD | 105.11% |
| 2020 Q2 | -95.71 Thousand USD | 68.38% |
| 2020 Q1 | -302.68 Thousand USD | 62.34% |
| 2020 FY | 21.54 Thousand USD | 102.68% |
| 2019 Q2 | -2.02 Million USD | -79.11% |
| 2019 FY | -803.81 Thousand USD | 27.5% |
| 2019 Q4 | -803.81 Thousand USD | 41.42% |
| 2019 Q3 | -1.37 Million USD | 32.24% |
| 2019 Q1 | -1.13 Million USD | -1.99% |
| 2018 Q3 | -1.44 Million USD | -81.06% |
| 2018 Q1 | -1.57 Million USD | -357.2% |
| 2018 FY | -1.1 Million USD | -222.19% |
| 2018 Q4 | -1.1 Million USD | 23.05% |
| 2018 Q2 | -795.75 Thousand USD | 49.42% |
| 2017 Q3 | -887.36 Thousand USD | 46.0% |
| 2017 Q2 | -1.64 Million USD | 29.76% |
| 2017 Q1 | -2.33 Million USD | 66.02% |
| 2017 FY | -344.11 Thousand USD | 95.0% |
| 2017 Q4 | -344.11 Thousand USD | 61.22% |
| 2016 Q1 | -118.62 Thousand USD | 83.21% |
| 2016 Q2 | -4.61 Million USD | -3790.54% |
| 2016 Q3 | -3.55 Million USD | 23.0% |
| 2016 Q4 | -6.88 Million USD | -93.75% |
| 2016 FY | -6.88 Million USD | -1044.81% |
| 2015 Q2 | -1.89 Million USD | -2155.57% |
| 2015 Q3 | -1.24 Million USD | 34.34% |
| 2015 FY | -601.44 Thousand USD | -64.71% |
| 2015 Q1 | -83.95 Thousand USD | 77.01% |
| 2015 Q4 | -706.61 Thousand USD | 43.16% |
| 2014 Q4 | -365.16 Thousand USD | -9.35% |
| 2014 FY | -365.16 Thousand USD | -635.34% |
| 2014 Q3 | -333.94 Thousand USD | -97.83% |
| 2014 Q2 | -168.8 Thousand USD | -318.53% |
| 2014 Q1 | 77.24 Thousand USD | 13.24% |
| 2013 Q1 | -776.47 Thousand USD | 9.47% |
| 2013 FY | 68.21 Thousand USD | 107.95% |
| 2013 Q4 | 68.21 Thousand USD | -0.15% |
| 2013 Q3 | 68.31 Thousand USD | 0.24% |
| 2013 Q2 | 68.15 Thousand USD | 108.78% |
| 2012 Q1 | -96.37 Thousand USD | 85.29% |
| 2012 Q2 | -461.92 Thousand USD | -379.3% |
| 2012 Q3 | -514 Thousand USD | -11.27% |
| 2012 Q4 | -857.7 Thousand USD | -66.87% |
| 2012 FY | -857.7 Thousand USD | -30.89% |
| 2011 Q4 | -655.3 Thousand USD | -119.41% |
| 2011 Q3 | 3.37 Million USD | -0.56% |
| 2011 FY | -655.3 Thousand USD | -119.33% |
| 2011 Q2 | 3.39 Million USD | 607.2% |
| 2011 Q1 | 480.03 Thousand USD | -85.84% |
| 2010 Q2 | 3.41 Million USD | -1.67% |
| 2010 Q4 | 3.38 Million USD | -2.24% |
| 2010 Q3 | 3.46 Million USD | 1.61% |
| 2010 Q1 | 3.47 Million USD | -7.37% |
| 2010 FY | 3.38 Million USD | -9.51% |
| 2009 Q2 | 4.72 Million USD | -11.5% |
| 2009 Q1 | 5.33 Million USD | 7.35% |
| 2009 FY | 3.74 Million USD | -24.67% |
| 2009 Q4 | 3.74 Million USD | -18.6% |
| 2009 Q3 | 4.6 Million USD | -2.58% |
| 2008 Q1 | 4.95 Million USD | 47.11% |
| 2008 Q3 | 4.42 Million USD | -3.75% |
| 2008 Q4 | 4.97 Million USD | 12.5% |
| 2008 FY | 4.97 Million USD | 47.72% |
| 2008 Q2 | 4.59 Million USD | -7.26% |
| 2007 Q3 | 6.04 Million USD | 34.3% |
| 2007 Q4 | 3.36 Million USD | -44.35% |
| 2007 Q2 | 4.5 Million USD | 112.55% |
| 2007 Q1 | 2.11 Million USD | 0.41% |
| 2007 FY | 3.36 Million USD | 59.52% |
| 2006 Q4 | 2.11 Million USD | 21.92% |
| 2006 FY | 2.11 Million USD | 23.54% |
| 2006 Q1 | 1.97 Million USD | 15.81% |
| 2006 Q2 | 1.86 Million USD | -5.7% |
| 2006 Q3 | 1.73 Million USD | -7.22% |
| 2005 Q4 | 1.7 Million USD | -17.39% |
| 2005 Q3 | 2.06 Million USD | -14.76% |
| 2005 Q1 | 1.83 Million USD | 4.9% |
| 2005 Q2 | 2.42 Million USD | 32.22% |
| 2005 FY | 1.7 Million USD | -2.34% |
| 2004 Q2 | 769.67 Thousand USD | -67.54% |
| 2004 Q1 | 2.37 Million USD | -30.98% |
| 2004 FY | 1.74 Million USD | -49.09% |
| 2004 Q4 | 1.74 Million USD | 77.73% |
| 2004 Q3 | 984.06 Thousand USD | 27.86% |
| 2003 Q4 | 3.43 Million USD | 2.13% |
| 2003 Q2 | 3.52 Million USD | -4.12% |
| 2003 FY | 3.43 Million USD | -5.5% |
| 2003 Q1 | 3.67 Million USD | 1.2% |
| 2003 Q3 | 3.36 Million USD | -4.64% |
| 2002 Q4 | 3.63 Million USD | 0.38% |
| 2002 Q1 | 3.81 Million USD | -5.66% |
| 2002 Q2 | 3.84 Million USD | 0.85% |
| 2002 Q3 | 3.62 Million USD | -5.81% |
| 2002 FY | 3.63 Million USD | -10.05% |
| 2001 Q3 | 4.05 Million USD | 7.72% |
| 2001 FY | 4.04 Million USD | 5.44% |
| 2001 Q1 | 4.04 Million USD | 5.46% |
| 2001 Q2 | 3.76 Million USD | -6.92% |
| 2001 Q4 | 4.04 Million USD | -0.27% |
| 2000 Q3 | 2.32 Million USD | -44.42% |
| 2000 Q4 | 3.83 Million USD | 64.67% |
| 2000 FY | 3.83 Million USD | -13.88% |
| 2000 Q1 | 4.49 Million USD | 0.95% |
| 2000 Q2 | 4.18 Million USD | -6.78% |
| 1999 Q1 | 2.8 Million USD | 33.33% |
| 1999 Q2 | 3.8 Million USD | 35.71% |
| 1999 FY | 4.45 Million USD | 111.91% |
| 1999 Q4 | 4.45 Million USD | 12.66% |
| 1999 Q3 | 3.95 Million USD | 3.95% |
| 1998 FY | 2.1 Million USD | 135.0% |
| 1998 Q1 | -1.3 Million USD | 78.33% |
| 1998 Q2 | -300 Thousand USD | 76.92% |
| 1998 Q3 | 200 Thousand USD | 166.67% |
| 1998 Q4 | 2.1 Million USD | 950.0% |
| 1997 Q2 | -7.95 Million USD | 0.0% |
| 1997 Q3 | 1.6 Million USD | 120.13% |
| 1997 Q4 | -6 Million USD | -475.0% |
| 1997 FY | -6 Million USD | -5900.0% |
| 1996 FY | -100 Thousand USD | -211.11% |
| 1995 FY | 90 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | -674702.443% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 256.504% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 120.657% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -3441.348% |
| Rebus Holdings, Inc. | 305 Thousand USD | 2998.332% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | -40.215% |
| Qrons Inc. | 351.42 Thousand USD | 2615.433% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 1520.376% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 120.353% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -43215.915% |
| Skye Bioscience, Inc. | -5.72 Million USD | -54.506% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 156.08% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 314.664% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 2299.809% |
| SQZ Biotechnologies Company | -36.23 Million USD | 75.606% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 494.246% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 1053.413% |
| Mesoblast Limited | 55.85 Million USD | 115.826% |
| Marizyme, Inc. | 18.56 Million USD | 147.606% |
| Genus plc | 190.6 Million USD | 104.638% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 495.375% |
| Pharming Group N.V. | 109.8 Million USD | 108.051% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 1127.609% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 828.231% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 1399.987% |
| ContraFect Corporation | -6.02 Million USD | -46.696% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 6665.64% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 865.076% |
| IMV Inc. | 7.67 Million USD | 215.245% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 260.67% |
| MultiCell Technologies, Inc. | 90.04 USD | 9817860.995% |
| ONE Bio Corp. | 9.04 Million USD | 197.786% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -1104.384% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 168.283% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 746.206% |
| Q BioMed Inc. | 4.06 Million USD | 317.731% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 128.932% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 977.223% |
| Biomind Labs Inc. | 711.4 Thousand USD | 1342.604% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 114.6% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 542.13% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 169.026% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 2557.511% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 6423.075% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 44595.455% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 501.453% |
| GB Sciences, Inc. | 1.74 Million USD | 605.914% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -4709.842% |
| HST Global, Inc. | 96.79 Thousand USD | 9232.801% |
| CSL Limited | 10.52 Billion USD | 100.084% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 4386.704% |
| Halberd Corporation | 144.72 Thousand USD | 6208.244% |
| Enzolytics Inc. | 981.65 Thousand USD | 1000.51% |
| Agentix Corp. | 37.63 Thousand USD | 23591.037% |
| Resverlogix Corp. | 6.45 Million USD | 237.032% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -1213.335% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -2.02 Billion USD | 99.564% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 81.196% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 225.017% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 426.363% |
| GeneThera, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | -5.9 Million USD | -49.748% |
| Zenith Capital Corp. | 10.06 Thousand USD | 87936.963% |
| Genscript Biotech Corporation | -1.06 Billion USD | 99.167% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 4510.429% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 470.486% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 5473.513% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -48158.063% |
| Kadimastem Ltd | -253.1 Thousand USD | -3392.628% |
| Helix BioMedix, Inc. | -2.57 Million USD | -243.961% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 143.598% |
| BioStem Technologies, Inc. | 4.47 Million USD | 297.672% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 4492.416% |
| LadRx Corporation | -2.03 Million USD | -334.08% |
| Cell Source, Inc. | 9.23 Million USD | 195.753% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 1491.746% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 1491.746% |
| NovAccess Global Inc. | 2.17 Million USD | 505.786% |
| Affymax, Inc. | -5.59 Million USD | -57.94% |
| Itoco Inc. | 228.3 Thousand USD | 3971.975% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 6600.461% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 278.332% |
| Mobile Lads Corp. | 484.23 Thousand USD | 1925.553% |
| CytoDyn Inc. | 20.26 Million USD | 143.628% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -1366192.427% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -95277.511% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 214.715% |
| SYBLEU INC | 473.71 Thousand USD | 1966.086% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 298.337% |
| International Stem Cell Corporation | 2.59 Million USD | 441.309% |
| Bioxytran, Inc. | 1.89 Million USD | 565.525% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 14263.575% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 505.333% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 357.423% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 203.355% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 1244.167% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -607.193% |
| Neutra Corp. | 52.18 Thousand USD | 17038.916% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -255.159% |
| PureTech Health plc | -167.19 Million USD | 94.713% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -3509.483% |
| IXICO plc | -4.44 Million USD | -98.892% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 166.873% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 116.116% |
| CSL Limited | 10.52 Billion USD | 100.084% |
| Cellectis S.A. | -43.81 Million USD | 79.826% |